



HAL
open science

Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives

Léo Mas, Lilian Schwarz, Jean-Baptiste Bachet

► To cite this version:

Léo Mas, Lilian Schwarz, Jean-Baptiste Bachet. Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives. *Current Opinion in Oncology*, 2020, 32 (4), pp.356-363. 10.1097/CCO.0000000000000639 . hal-03013625

HAL Id: hal-03013625

<https://hal.sorbonne-universite.fr/hal-03013625v1>

Submitted on 19 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title: Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives

Authors: Léo MAS,¹ Lilian SCHWARZ,^{2,3} Jean-Baptiste BACHET^{1,4}

Affiliations: ¹ Department of Hepato-gastroenterology, Groupe Hospitalier Pitié Salpêtrière, Paris, France; ² Department of Digestive Surgery, Rouen University Hospital, Rouen, France; ³ Department of Genomic and Personalized Medicine in Cancer and Neurological Disorders, Normandie University, UNIROUEN, UMR 1245 INSERM, Rouen University Hospital, Rouen, France; ⁴ Sorbonne University, UPMC University, Paris, France

Corresponding author: Jean-Baptiste Bachet, MD, PhD

Service d'Hépatogastroentérologie et Oncologie Digestive, Groupe Hospitalier Pitié Salpêtrière, 47-83 Boulevard de l'Hôpital, 75651 Paris Cedex 13; Phone: 00 33 1 42 16 10 41, Fax: 00 33 1 42 16 12 38, Email : jean-baptiste.bachet@aphp.fr

Abstract

Purpose of the review:

The modalities of management of resectable pancreatic ductal adenocarcinoma (PDAC) have evolved in recent years with new practice guidelines on adjuvant chemotherapy and results of randomized phase III trials. The aim of this review is to describe the state of the art in this setting and to highlight future possible perspectives.

Recent findings:

Resectable PDAC is the tumor without vascular contact or a limited venous contact without vein irregularity. Several pathologic and biologic robust prognostic factors such as an R0 resection defined by a margin ≥ 1 mm have been validated. In phase III trials, the doublet gemcitabine-capecitabine provided a statistically significant, albeit modest overall survival benefit, but failed to show an improvement in relapse-free survival. Similarly, gemcitabine plus nab-paclitaxel did not increase disease-free survival. Modified FOLFIRINOX led to improved disease-free survival, overall survival, and metastasis-free survival, with acceptable toxicity. In the future, prognostic and/or predictive biomarkers could lead the optimization of therapeutic strategies and neoadjuvant treatment could become a standard of care in PDAC.

Summary:

After curative intent resection, modified FOLFIRINOX is the standard of care in adjuvant in fit PDAC patients. Others regimens (monotherapy or gemcitabine-based) are an option in unfit patients.

Key words:

Pancreatic ductal adenocarcinoma, definition, FOLFIRINOX, biomarker, neoadjuvant

Introduction

Pancreatic ductal adenocarcinoma (PDAC) is the second most common digestive cancer in Western countries [1,2] with a regularly increasing incidence and is projected to become the second cause of cancer-related death between 2020 and 2030.[3]

Many of the older studies included patients with both metastatic and locally advanced PDACs in the same cohorts. During the past decade, learned societies recommended carrying out studies dedicated to treatment of these two different group of patients.[4,5] Thereafter, locally advanced PDAC subgroup was divided into « true » locally advanced tumors with a low rate of secondary resection and borderline tumors for which secondary resection is possible after induction treatment (about two third of cases in recent studies).[6,7*] Most of the proposed classifications for borderline tumors are based on the degree of arterial and/or venous contact of the tumor, however an international consensus recently suggested adding an Eastern Cooperative Oncology Group performance status and biological factors aside from anatomical criteria.[8-12] Thus, at diagnosis, only 10%-15% of patients have a resectable PDAC.

To date, resection remains the only potentially curative-intent treatment and upfront surgery remains the standard of care for patients with resectable PDAC.[13,14] While the benefit of adjuvant chemoradiotherapy (CRT) is a matter of debate, adjuvant chemotherapy has been a standard for over a decade now.[13-17] Three chemotherapy regimens, gemcitabine plus erlotinib (Roche[®], Bâle, Switzerland), modified FOLFIRINOX (5-fluorouracil, oxaliplatin, and irinotecan), and gemcitabine plus nab-paclitaxel (Celgene[®], Summit, New Jersey, USA) were found to be significantly superior to gemcitabine monotherapy in advanced stage pancreatic cancer,[18-20] and have subsequently been assessed in the adjuvant setting.[21,22**,23**] Several adjuvant randomized phase III trials have been published until now.[15-17,21-25] Standard chemotherapy regimens and robust prognostic factors that are

used after upfront surgery are now validated and a number of promising biomarkers have been reported. In addition, new therapeutic strategies are currently being evaluated with the development of novel neoadjuvant strategies.

The aim of this review is to describe the state of the art in the adjuvant setting of PDAC and to highlight future possible perspectives.

Text of review

1. Resectable Tumor

Definition

Many expert consensus groups have proposed definitions of borderline PDAC tumors in order to further improve the criteria for resectability at diagnosis, with the primary objective being a margin-negative resection (R0). Currently, a resectable PDAC is defined by the absence of vascular tumor contact or $\leq 180^\circ$ contact with the superior mesenteric vein (SMV) or portal vein (PV) without vein contour irregularity (stenosis, deformity).[14,26] For the tumors of the body and/or tail of the pancreas, invasion of splenic vessels (artery and/or vein) is not a contraindication to upfront surgery. The presence of peri-pancreatic lymph nodes on the imaging assessment likewise does not a resection. Contrarily, in patients with distant lymph node involvement surgery should not be considered.[27-29]

A thoraco-abdomino-pelvien multi-detector computed tomography with intravenous contrast injection and fine sections on pancreatic area is a key diagnostic technique, allowing the assessment of locoregional and distant extensions.[14,26] Recently, some studies have highlighted the potential of adding a magnetic resonance imaging (MRI) with diffusion-weighted to this exam. Such approach has been suggested to increase the diagnosis of undiscovered infracentimetric liver metastases by 10%-15%.[30] The recently published French clinical practice guidelines indicate that a liver MRI at diagnosis is an option in patients with localized PDAC.[31] Histological proof of PDAC is not usually required before surgery if the medical history, symptoms, and imagery data are concordant with the diagnosis. However, this confirmation has to be obtained in case of doubt about the diagnosis or when neoadjuvant treatment is planned.[14,26,31]

Data on adjuvant chemotherapy in PDAC discussed below apply to resectable tumors defined along these criteria.

Prognostic factors

Carbohydrate antigen (CA) 19-9, a sialylated Lewis A blood group antigen, is currently the only biomarker validated in PDAC. This factor was found to be useful for monitoring treatment efficacy and follow-up after curative intent surgery, but not for screening.[14,26,31]

While the CA 19-9 can be elevated in case of biliary obstruction or others cancers, it is normal in patients with a Lewis-negative genotype, present in about 5%-10% of the white population.[32] In case of resectable PDAC tumors, the level of pre-operative CA 19-9 is highly prognostic and some authors have proposed various cut-off values to define the resectability (from 100 to 500 U/ml),[12,33] in the absence of vascular involvement. Until now, at the exception of the International Association of Pancreatology, there is no pre-operative cut-off point recommended by the oncologic societies guidelines.[12,14,26,31] The level of post-operative CA 19-9 is also highly prognostic.[24,25] Moreover, it is noteworthy that the latter was added as an inclusion criteria in two recent adjuvant randomized phase III trials (the cut-off of ≤ 180 U/ml in PRODIGE24 and of < 100 U/ml in AFACT).[22,23]

Patients undergoing SMV or PV resection has been reported to be have worse prognosis.[34] This finding has led to restriction of the resecability definition to the PDAC tumors with limited vein contact ($< 180^\circ$) and without contour irregularity.[11,14,26,31] Such defined resection was of poor prognosis in the ESPAC4 and PRODIGE24 trials. [22,25] and venous resections have to be reported in future adjuvant trials.

Several studies have reported variety of robust pathologic prognostic factors including grade of tumoral differentiation, N and T stage (maximal tumor diameter), and the resection margin status of which.[15-17,22,24,25] Most of these factors have subsequently been validated. The

definitions of T and N categories have been modified in the 8th version of American Joint Committee on Cancer (AJCC) TNM classification,[35] that recommends to look at least 15 lymph nodes to distinguish the N stage.[36] Historically among patients with PDAC, no consensual precise definition of the R0 resection margin and the modalities of its assessment were defined. Therefore, the R1-resection rate differs between adjuvant randomized phase III trials, ranging from 16% reported in the ESPAC1 trial to 61% in the ESPAC4 study.[15-17,22-25] According to the British College of Pathologists guidelines that have been validated by the International Study Group of Pancreatic Surgery, a positive-R1 resection margin is currently defined as < 1 mm.[10,14,31] Different surgical margins (anterior, posterior, medial, or SMV groove, superior mesenteric artery, pancreatic transection, bile duct, and enteric) have to be clearly identify by surgeon, at best by inking them with different colors.[10,37] In most studies on adjuvant chemotherapy for PDAC, the efficacy of this treatment on survival was reported in all subgroups defined by the grade of differentiation, N stage, T stage and the resection margin status.[15-17,22-25] Although, adjuvant chemotherapy is indicated in all patients who undergo curative intent resection of PDAC, a recent retrospective analysis from the US National Cancer database has suggested that patients with infra-centimetric PDAC (T1aN0 or T1bN0) may not necessary require this treatment.[38*] Indication of adjuvant chemotherapy in PDAC patients with infra-centimetric tumor should be discussed during multidisciplinary team meeting.

2. Adjuvant treatment

Adjuvant chemoradiotherapy

Adjuvant CRT was not associated with a clinical benefit in the ESPAC-1 trial and the results of this study actually suggested that it might even be harmful.[15] This trial had however

some limitations as neither the protocol of CRT used was optimal according to current standards and nor quality control for CRT was planned in this trial. In fact, the interest of adjuvant CRT is discussed and debated in the published literature with several studies reporting discordant results.[37,38] The meta-analysis of pooling patient data from five adjuvant randomized trials has suggested that patient with R1 resection could benefit from adjuvant CRT.[41] However, the R1 rate ranging from 17% to 82% across studies highlighted high heterogeneity in evaluation of the resection margin preventing any clear conclusions. Adjuvant CRT is not recommended by all oncologic guidelines.[14,26,31] The RTOG 0848 trial assessing the role of CRT after adjuvant gemcitabine (ClinicalTrials.gov identifier: NCT01013649) is ongoing and results are expected shortly. Patients without evidence of relapse after 5 cycles of gemcitabine are randomized between one more cycle of chemotherapy alone or one more cycle of chemotherapy followed by CRT.

Adjuvant monochemotherapy

The benefit of adjuvant chemotherapy has been demonstrated in the ESPAC-1 trial (5-fluorouracil [5FU] bolus; Mayo clinical FUFOL regimen for 6 months) and in the CONKO-001 trial (gemcitabine for 6 months).[15-17] These two regimens have been directly compared in the ESPAC-3 trial.[24] The oncological results obtained were strictly identical, but the safety profile was better with gemcitabine, positioning 5FU as an alternative treatment option. It should be noted that unlike for colorectal cancers, the LV5FU2 protocol (bolus 5FU then continuous 5FU over 46h) or capecitabine monotherapy were not evaluated as adjuvant treatment after resection of PDAC.

Summary of results from major phase III trials of adjuvant chemotherapy after curative resection of pancreatic ductal adenocarcinoma are presented in Table 1. Adjuvant gemcitabine monotherapy has been the standard of care for more than a decade.

Adjuvant gemcitabine-based chemotherapy

Several randomized clinical trials have evaluated the value of adding an additional drug to gemcitabine in the adjuvant setting following encouraging results from studies in metastatic PDAC.[18-20]

The erlotinib plus gemcitabine regimen was associated with increased overall survival (OS; HR=0.82, 95% CI 0.69-0.99; p=0.038) in comparison to gemcitabine alone in patients with advanced PDAC.[18] Although statistically significant, the OS benefit was not clinically relevant with an only 14-day median difference. Therefore, this protocol was not considered as a standard, but more as an option. Adding erlotinib to gemcitabine did not increase disease-free survival (DFS) or OS in the adjuvant CONKO-005 trial (Table 1)[21] and showed no benefit in the LAP07 trial of patients with locally advanced PDAC.[42]

Two randomized phase III trials reported an increase in progression-free survival (PFS), but not in OS by the addition of capecitabine to gemcitabine in patients with advanced PDAC.[43,44] Following these findings, the ESPAC-4 trial compared the gemcitabine plus capecitabine (GEMCAP) combination to gemcitabine monotherapy in the adjuvant setting.[25] This trial was positive for its main objective with a significant but modest increase in OS with the 5-year survival rate of 28.8% (vs 16.3%; Table 1). Nevertheless, these results have been criticized, in particular because of the absence of a significant relapse-free survival (RFS) difference between the two arms despite a trend in favor of the GEMCAP arm (the 3 and 5-year survival rate of 23.8% and 18.6% with GEMCAP and 20.9% and 11.9% with monotherapy, respectively). The GEMCAP protocol was also associated with a poorer safety profile (Table 2).

Finally, the gemcitabine plus nab-paclitaxel (GEMNAB) combination has been evaluated in adjuvant randomized phase III APACT trial.[19,23**] The study did not meet its main

objective, the DFS in centralized reviewing (GEMNAB 19.4 months vs gemcitabine 18.8 months [HR=0.88; p=0.182]). In per-investigator analysis, GEMNAB conferred a significant but modest benefit in DFS, (Table 1) and a significant increase in OS. The toxicity profiles corresponded to those expected with significantly more toxicities in the GEMNAB arm (Table 2).

Adjuvant modified FOLFIRINOX

In metastatic PDAC, the FOLFIRINOX protocol has demonstrated its superiority compared to gemcitabine.[20] This protocol was further evaluated in the PRODIGE24 trial in the adjuvant setting.[22**] To improve the tolerability, 5FU bolus was removed. The dose of irinotecan had to be reduced from 180 mg/m² to 150 mg/m² (modified FOLFIRINOX [mFOLFIRINOX]) due to a grade 3-4 diarrhea rate greater than 20% at the first planned interim analysis. The mFOLFIRINOX regimen was associated with a significant increase in DFS (the 3-year rate 39.7% vs 21.4%), OS (the 3-year rate 63.4% vs 48,6%), and metastasis-free survival (Table 1). The benefit of mFOLFIRINOX chemotherapy was found in all of the predefined subgroups with a statistically significant survival improvement in patients older than 65 years (n=201, 41%) and a trend in patients older than 70 years (n=101, 20%). There was no difference in neutropenia rates between the two arms, but 62% of patients in the mFOLFIRINOX arm had received granulocyte-colony stimulating factor. mFOLFIRINOX was associated with more mucositis, diarrhea, fatigue, vomiting, and neuropathy (Table 2), but these toxicities were manageable and no toxic deaths were reported. Diarrhea was most frequent in patients with a higher number of lymph nodes (≥ 20 vs < 20 ; adjusted odds ratio, 2.4; 95% CI 1.3-4.4; p<0.001), which was expected given that extensive lymphadenectomy can be associated with more diarrhea in post-operative treatment but not with better oncologic outcomes.[36] Gemcitabine chemotherapy resulted in more thrombocytopenia and flu-like

illness. Overall, 66% of patients from the mFOLFIRINOX arm and 79% from the gemcitabine arm received all of the scheduled cycles.

Summary of adjuvant chemotherapy phase III trials

Considering the remarkable results of the PRODIGE24 trial, mFOLFIRINOX is now the standard adjuvant chemotherapy regimen in fit PDAC patients, while GEMCAP or monotherapies with gemcitabine or 5FU are validated treatment options in unfit patients. Gemcitabine monotherapy should be preferred over 5FU based on the better safety profile, while no consensus exists to favor GEMCAP over gemcitabine monotherapy. These regimens are proposed as equivalent updated options in the latest ASCO guidelines.[45] Although the APACT trial was negative for its primary objective, future indications of the GEMNAB regimen will need to be clarified in clinical guidelines given the positive per-investigator DFS and OS results.

3. Perspectives

Promising biomarkers

At least two major lines of research are currently underway to improve oncological results using biomarkers.

The first line of research has been undertaken in order to better define the optimal chemotherapy to use in the adjuvant setting for PDAC according to intra-tumoral expression of predictive biomarkers. Among these, the levels of intra-tumoral expression of human equilibrative nucleoside transporter 1 (hENT1) and deoxycytidine kinase (dCK) have proven to be the most promising potential biomarkers of the gemcitabine efficacy.[46-51]

Nevertheless, discordant results have been reported due to the use of antibodies not equivalent

in activity.[46-53*] The level of dihydropyrimidine dehydrogenase (DPD) expression could also be predictive of the 5FU efficacy.[51*] Similarly, the recent molecular signatures (based on mRNA expression profiles) could also be predictive of chemotherapy efficacy, but there are no data in the adjuvant setting.[54*]

The second line of research has been undertaken to better define the patients with a resectable PDAC who will benefit the most from an upfront surgery. In fact, the risk of relapse remains very high after curative intent surgery, superior to 60%,[22] and PDAC is commonly considered as a systemic disease. The detection of circulating prognostic biomarkers could help to identify the patients who have the highest risk of early relapse after surgery and to propose them alternative therapeutic strategies (e.g. neoadjuvant chemotherapy). For instance, patients with detectable circulating tumor DNA before surgery do not seem benefit from upfront surgery.[55,56*] Others circulating biomarkers such as circulating tumor cells or exosomes are promising and could also be used as reliable markers of treatment efficacy.[57,58]

However, robust and reproducible methodologies to assess these biomarkers have to be developed and prospectively validated before any used in routine practice.

Neoadjuvant strategies

Like for gastric or rectal cancers, development of neoadjuvant strategies could allow to improve oncologic outcomes of patients with resectable PDAC. After pancreatic resection, about one third of patients cannot receive an adjuvant treatment because of postoperative morbidity and mortality.[59,60] Moreover, the rate of relapse remains superior to 60% in adjuvant phase III trials in which only fit patients have been included.[22-25] Data from the recent studies of patients with borderline PDAC have shown that neoadjuvant/induction strategies (most often, chemotherapy follow or not by CRT) were well tolerated and did not

impair the morbidity and mortality after secondary pancreatic resection, and even reduced the rate of pancreatic fistula.[6,7*,59-61] Moreover, and like in others digestive cancers, the pathologic response is a prognostic factor after neoadjuvant/induction treatment.[61] Promising preliminary results of the PREOPANC-1 trial assessing a neoadjuvant/induction strategy coupling gemcitabine and CRT in patients with resectable and borderline PDAC have been presented,[66] and several randomized neoadjuvant phase II and III trials are currently ongoing.[63-66]

Conclusions

The definition of resectable PDAC has evolved in recent years, but upfront surgical resection remains the standard of care in this disease setting. The mFOLFIRINOX regimen is now the adjuvant standard in fit patients. Modified FOLFIRINOX, gemcitabine-based regimens (GEMNAB, GEMCAP), monotherapy with gemcitabine or with 5-fluorouracil are the alternative options in unfit PDAC patients. Several promising predictive or prognostic biomarkers have been proposed, but they still need prospective validation. Neoadjuvant treatment will likely shape the future in this setting and several randomized trials are currently ongoing.

Key points

- Resectable PDAC is defined as the tumor without vascular contact or $\leq 180^\circ$ contact with the superior mesenteric vein (SMV), or portal vein (PV) without vein contour irregularity.
- Upfront surgery remains the standard of care for resectable PDAC and robust and validated biological and pathological factors coupled with the sound international guidelines are in place.
- In fit patients, the modified FOLFIRINOX regimen is now the standard treatment after curative intent surgery of PDAC, while the gemcitabine-base regimens (GEMCAP or GEMNAB) or monotherapies are an option in unfit patients.
- Prospective validation of methodologies used to assess promising predictive and/or prognostic biomarkers and of steps that lead to interest in a specific therapeutic strategy with their use are necessary before these are applied in routine clinical practice.
- Neoadjuvant treatment strategies are probably the future and several randomized trials are ongoing.

Acknowledgements

Acknowledgements: The authors thank Magdalena Benetkiewicz for editorial assistance.

Financial support and sponsorship: none

Conflict of interest: LM: none; LS received fees from Bayer, Servier, Sanofi, Mayoly Spindler, Intuitive, Roche; JBB serves as a board member and/or received fees from Amgen, AstraZeneca, Bayer, Celgene, Merck Serono, Mundipharma, Pierre Fabre, Roche, Sanofi, Shire, Servier.

References

1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer* 2018; 103:356-387.
 2. Siegel RL, Miller KD, Jemal A. Cancer statistics 2019. *CA Cancer J Clin* 2019; 69:7-34.
 3. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014; 74:2913-2921.
 4. Philip PA, Mooney M, Jaffe D, et al. Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. *J Clin Oncol* 2009; 27:5660-5669.
 5. Van Laethem JL, Verslype C, Iovanna JL, et al. New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel. *Ann Oncol* 2012; 23:570-576.
 6. Katz MH, Shi Q, Ahmad SA, et al. Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. *JAMA Surg* 2016; 151:e161137.
 7. Murphy JE, Wo JY, Ryan DP, et al. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol* 2018; 4:963-969.
- * One of the first strategic phase II trials (based on induction chemotherapy response) in patients with borderline resectable PDAC.

8. Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. *Ann Surg Oncol* 2009; 16:1727-1733.
9. Abrams RA, Lowy AM, O'Reilly EM, et al. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. *Ann Surg Oncol* 2009; 16:1751-1756.
10. Bockhorn M, Uzunoglu FG, Adham M, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). *Surgery* 2014; 155:977-988.
11. Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. *Radiology* 2014; 270:248-260.
12. Isaji S, Mizuno S, Windsor JA, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. *Pancreatology* 2018; 18:2-11.
13. Tempero MA, Malafa MP, Chiorean EG, et al. Pancreatic Adenocarcinoma, Version 1.2019. *J Natl Compr Canc Netw* 2019; 17:202-210.
14. Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2015; 26 Suppl 5:v56-68.
15. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *N Engl J Med* 2004; 350:1200-1210.
16. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. *JAMA* 2007; 297:267-277.

17. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. *JAMA* 2013; 310:1473-1481.
 18. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; 25:1960-1966.
 19. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013; 369:1691-1703.
 20. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011; 364:1817-1825.
 21. Sinn M, Bahra M, Liersch T, et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. *J Clin Oncol* 2017; 35:3330-3337.
 22. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. *N Engl J Med* 2018; 379:2395-2406.
- ** Randomized phase III trial that validated modified FOLFIRINOX as the new standard in adjuvant.
23. Tempero MA, Reni M, Riess H, et al. APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. *J Clin Oncol* 2019; 37(no. 15_suppl): 4000-4000.
- ** Randomized phase III trial that assessed gemcitabine plus nab-paclitaxel regimen in adjuvant.

24. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. *JAMA* 2010; 304:1073-1081.
25. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *Lancet* 2017; 389:1011-1024.
26. Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017; 15:1028-1061.
27. Agalianos C, Gouvas N, Papaparaskeva K, Dervenis C. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. *HPB (Oxford)* 2016; 18:633-641.
28. Paiella S, Sandini M, Gianotti L, et al. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis. *Eur J Surg Oncol* 2016; 42:616-624.
29. Schwarz L, Lupinacci RM, Svrcek M, et al. Para-aortic lymph node sampling in pancreatic head adenocarcinoma. *Br J Surg* 2014; 101:530-538.
30. Kim HW, Lee JC, Paik KH, et al. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. *Surgery* 2017; 161:1579-1587.
31. Neuzillet C, Gaujoux S, Williet N, et al. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). *Dig Liver Dis* 2018; 50:1257-1271.

32. Galli C, Basso D, Plebani M. CA 19-9: handle with care. *Clin Chem Lab Med* 2013; 51:1369-1383.
33. Khorana AA, Mangu PB, Berlin J, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016; 34:2541-2556.
34. Giovinazzo F, Turri G, Katz MH, et al. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. *Br J Surg* 2016; 103:179-191.
35. Kamarajah SK, Burns WR, Frankel TL, et al. Validation of the American Joint Commission on Cancer (AJCC) 8th Edition Staging System for Patients with Pancreatic Adenocarcinoma: A Surveillance, Epidemiology and End Results (SEER) Analysis. *Ann Surg Oncol* 2017; 24:2023-2030.
36. Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). *Surgery* 2014; 156:591-600.
37. Delpero JR, Jeune F, Bachellier P, et al. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. *Ann Surg* 2017; 266:787-796.
38. Shaib WL, Narayan AS, Switchenko JM, et al. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. *Cancer* 2019;125:57-67.
- * Retrospective cohort study that evaluated the benefit of adjuvant therapy in patients with T1 PDAC.
39. Ren F, Xu YC, Wang HX, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, for resectable advanced pancreatic adenocarcinoma: continue or stop? *Pancreatology* 2012; 12:162-169.

40. Morganti AG, Falconi M, van Stiphout RG, et al. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2014; 90:911-917.
41. Stocken DD, Büchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. *Br J Cancer* 2005; 92:1372-1381.
42. Hammel P, Huguet F, van Laethem JL, et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. *JAMA* 2016; 315:1844-1853.
43. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. *J Clin Oncol* 2007; 25:2212-2217.
45. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 2009; 27:5513-5518.
45. Khorana AA, McKernin SE, Katz MHG. Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update Summary. *J Oncol Pract* 2019 ; 15 :454-457.46.
- Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. *Gastroenterology* 2009; 136:187-195.
47. Maréchal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. *Gastroenterology* 2012; 143:664-674.

48. Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. *J Natl Cancer Inst* 2014; 106:djt347.

49. Sinn M, Riess H, Sinn BV, et al. Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial. *Eur J Cancer* 2015; 51:1546-1554.

50. Wei CH, Gorgan TR, Elashoff DA, et al. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers. *Pancreas* 2013; 42:1303-1310.

51. Elander NO, Aughton K, Ghaneh P, et al. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. *Br J Cancer* 2018; 118:947-954.

* Retrospective analysis from the ESPAC4 trial that evaluated the predictive value of hENT1 and DPD for the benefit of gemcitabine and 5FU, respectively.

52. Svrcek M, Cros J, Maréchal R, et al. Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies. *Histopathology* 2015; 66:457-462.

53. Raffenne J, Nicolle R, Puleo F, et al. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. *Cancers (Basel)* 2019; 11(11).

* Large translational study comparing the different hENT1 antibodies available as well as the expression of mRNA.

54. Aung KL, Fischer SE, Denroche RE, et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. *Clin Cancer Res* 2018; 24:1344-1354.

* Preliminary results of the first prospective study evaluating prognostic and predictive value of molecular signature in patients with advanced PDAC.

55. Pietrasz D, Pécuchet N, Garlan F, et al. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. *Clin Cancer Res* 2017; 23:116-123.

56. Lee JS, Rhee TM, Pietrasz D, et al. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. *Sci Rep* 2019; 9:16971.

* Meta-analysis on prognostic value of ctDNA before or after PDAC resection.

57. Poruk KE, Valero V 3rd, Saunders T, et al. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. *Ann Surg* 2016; 264:1073-1081.

58. Allenson K, Castillo J, San Lucas FA, et al. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. *Ann Oncol* 2017; 28:741-747.

59. DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. *Ann Surg* 2006; 244:931-937.

60. Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. *Ann Surg* 2006; 244:10-15.

61. Pietrasz D, Marthey L, Wagner M, et al. Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. *Ann Surg Oncol* 2015;22 Suppl 3:S1196-1205.

62. Van Tienhoven G, Versteijne E, Suker M, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-

1): A randomized, controlled, multicenter phase III trial. *J Clin Oncol* 2018; 36(18_suppl):LBA4002.

63. Motoi F, Kosuge T, Ueno H, et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). *Jpn J Clin Oncol* 2019; 49:190-194.

64. Schwarz L, Vernerey D, Bachet JB, et al. Resectable pancreatic adenocarcinoma neoadjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). *BMC Cancer* 2018; 18:762.

65. Labori KJ, Lassen K, Hoem D, et al. Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial. *BMC Surg* 2017; 17:94.

66. Ettrich TJ, Berger AW, Perkhofer L, et al. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. *BMC Cancer* 2018; 18:1298.

Table 1: Major phase III trials of adjuvant chemotherapy after curative resection of pancreatic ductal adenocarcinoma [15-17, 21- 25]

Trial, Year	Arm of treatment	Number of patients	R1 resection rate	N+ rate	Venous resection	Disease-free survival months (95% CI)	HR (95% CI)	Overall survival months (95% CI)	HR (95% CI)
ESPAC-1, 2001	5FU bolus	147	19%	50%	ns	15.3 (10.5-19.2)	ns p=0.02	20.1 (16.5-22.7)	0.71 (0.55-0.92)
	Observation	142	16%	58%	ns	9.4 (8.4-15.2)		15.5 (13.0-17.7)	p=0.009
CONKO-001, 2007	Gem	179	19%	70%	ns	13.4 (11.6-15.3)	0.55 (0.44-0.69)	22.8 (18.5-27.2)	0.76 (0.61-0.95)
	Observation	175	15%	71%	ns	6.9 (6.0-7.5)	p<0.001	20.2 (17.7-22.8)	p=0.01
ESPAC-3, 2010	5FU bolus	551	35%	70%	16%	14.1 (12.5-15.3)	0.96 (0.84-1.10)	23.0 (21.1-25.0)	0.94 (0.81-1.08)
	Gem	537	35%	73%	13%	14.3 (13.5-15.6)	p=0.53	23.6 (21.4-26.4)	p=0.39
CONKO-005, 2017	Gem	217	0%	66%	ns	11.4 (9.2-13.6)	0.94 (0.76-1.15)	26.5 (22.4-30.6)	ns p=0.61
	Gem + Erlo	219	0%	64%	ns	11.4 (9.6-13.2)	p=0.26	24.5 (21.1-27.8)	
ESPAC-4, 2017	Gem	366	60%	82%	17%	13.1 (11.6-15.3)	0.86 (0.73-1.02)	25.5 (22.7-27.9)	0.82 (0.68-0.98)
	Gem + Cap	364	61%	79%	11%	13.9 (12.1-16.6)	p=0.082	28.0 (23.5-31.5)	p=0.032
PRODIGE 24, 2018	Gem	246	45%	75%	28%	12.8 (11.7-15.2)	0.58 (0.46-0.73)	35.0 (28.7-43.9)	0.64 (0.48-0.86)
	FOLFIRINOX	247	40%	78%	22%	21.6 (17.7-27.6)	p<0.001	54.4 (41.8-nr)	p=0.003
APACT, 2019	Gem	434	23%	72%	ns	13.7	0.82* (0.69-0.95)	36.2	0.82 (0.68-0.99)
	Gem + Nab	432	24%	72%	ns	16.6	p=0.017	40.5	p=0.045

Abbreviations: 5FU, 5-fluorouracil; Gem, gemcitabine; Erlo, erlotinib; Cap, capecitabine; Nab, CA, adjuvant chemotherapy; ns, non-specified; nr, not reached

* per-investigator analysis

Details of adjuvant chemotherapy protocols:

- 5FU bolus: leucovorin 20 mg/m² bolus follow by 5-fluorouracil 425 mg/m²/day bolus for 5 consecutive days, every 28 days, for a total of 6 cycles.
- Gem: gemcitabine 1000 mg/m² in 30 minutes intravenous (IV) at days 1, 8, and 15, one cycle every 28 days, for a total of 6 cycles.
- Gem + Erlo: gemcitabine 1000 mg/m² in 30 minutes IV at days 1, 8, and 15, plus erlotinib 100 mg/day from day 1 to day 28, one cycle every 28 days, for a total of 6 cycles.
- Gem + Cap: gemcitabine 1000 mg/m² in 30 minutes IV at days 1, 8, and 15, plus capecitabine 1660 mg/m²/day from day 1 to day 21, one cycle every 28 days, for a total of 6 cycles.
- FOLFIRINOX: oxaliplatin 85 mg/m², leucovorin 400 mg/m², irinotecan 150 mg/m² at day 1 follow by 5-fluorouracil 2400 mg/m² in 46h continuous infusion, one cycle every 14 days, for a total of 12 cycles.
- Gem + Nab: nab-paclitaxel 125 mg/m² in 30-40 minutes IV follow by gemcitabine 1000 mg/m² in 30 minutes IV at days 1, 8 and, 15, one cycle every 28 days, for a total of 6 cycles.

Table 2: Summary of main grade 3-4 adverse events reported in adjuvant randomized phase III trials [15-17, 21- 25]

Type of adverse events	Gemcitabine	5-fluorouracil (bolus)	Gemcitabine + erlotinib	Gemcitabine + capecitabine	Gemcitabine + nab-paclitaxel	mFOLFIRINOX*
Hematologic						
Neutropenia	22%-43%	22%	27%	38%	49%	34%
Febrile neutropenia	≤1%	ns	ns	ns	5%	4%
Anemia	1%-8%	ns	ns	2%	15%	3%
Thrombocytopenia	1%-6%	0%	5%	2%	ns	1%
Non-hematologic						
Fatigue	2%-6%	8%	5%	6%	10%	11%
Diarrhea	1%-4%	13%	5%	5%	5%	19%
Nausea	1%-2.5%	3.5%	ns	ns	ns	5.5%
Vomiting	1%-2%	3%	ns	ns	ns	5%
Stomatitis	0%	10%	ns	ns	ns	2.5%
Hand-foot syndrome	0%	ns	ns	7%		<1%
Peripheral neuropathy	0%	0%	0%	0%	15%	13%

Abbreviations: ns, not specified

*62.2% of patients received granulocyte-colony stimulating factor during adjuvant treatment